{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import dgipy"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Get Drug-Gene Interaction (DGI) Data\n",
    "Use DGIpy to query DGIdb for DGI data and drug applications for drugs of interest. The appNo's will be used to pull relevant FDA labels from the JSON dataset. The DGI data will eventually be linked up with whatever is extracted from the JSON dataset. The drugs of interest for this experiment are:  \n",
    "  \n",
    "- **Imatinib** (favorite test case)\n",
    "- **Encorafenib** (complex targeted therapy)\n",
    "- **Cisplatin** (common cancer therapy)\n",
    "- **Aspirin** (common therapy)\n",
    "- **FAKE** (fake)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>gene</th>\n",
       "      <th>approval</th>\n",
       "      <th>score</th>\n",
       "      <th>interaction_attributes</th>\n",
       "      <th>source</th>\n",
       "      <th>pmid</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>FIP1L1</td>\n",
       "      <td>True</td>\n",
       "      <td>2.199452</td>\n",
       "      <td>Fusion Protein: FIP1L1:PDGFRA</td>\n",
       "      <td>FDA Pharmacogenomic Biomarkers | PharmGKB - Th...</td>\n",
       "      <td>24433361</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ABL1</td>\n",
       "      <td>True</td>\n",
       "      <td>0.119476</td>\n",
       "      <td>Mechanism of Action: Inhibition| Endogenous Dr...</td>\n",
       "      <td>The ChEMBL Bioactivity Database | Drug Target ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>BIRC5</td>\n",
       "      <td>True</td>\n",
       "      <td>0.016854</td>\n",
       "      <td></td>\n",
       "      <td>NCI Cancer Gene Index</td>\n",
       "      <td>16254145</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ULK3</td>\n",
       "      <td>True</td>\n",
       "      <td>0.733151</td>\n",
       "      <td></td>\n",
       "      <td>PharmGKB - The Pharmacogenomics Knowledgebase</td>\n",
       "      <td>15073101</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>NF1</td>\n",
       "      <td>True</td>\n",
       "      <td>0.031876</td>\n",
       "      <td>Alteration: NF1:.| Alteration: NF1:del</td>\n",
       "      <td>Cancer Genome Interpreter</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>299</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>MPHOSPH8</td>\n",
       "      <td>True</td>\n",
       "      <td>0.003043</td>\n",
       "      <td></td>\n",
       "      <td>Drug Target Commons</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>300</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>MDM2</td>\n",
       "      <td>True</td>\n",
       "      <td>0.013811</td>\n",
       "      <td>Alteration: MDM2:amp</td>\n",
       "      <td>Cancer Genome Interpreter</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>301</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>MLLT3</td>\n",
       "      <td>True</td>\n",
       "      <td>0.179547</td>\n",
       "      <td></td>\n",
       "      <td>PharmGKB - The Pharmacogenomics Knowledgebase</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>302</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>MAPT</td>\n",
       "      <td>True</td>\n",
       "      <td>0.000814</td>\n",
       "      <td></td>\n",
       "      <td>Drug Target Commons</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>303</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>IFNG</td>\n",
       "      <td>True</td>\n",
       "      <td>0.025650</td>\n",
       "      <td></td>\n",
       "      <td>NCI Cancer Gene Index</td>\n",
       "      <td>8044830</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>304 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          drug      gene approval     score  \\\n",
       "0     IMATINIB    FIP1L1     True  2.199452   \n",
       "1     IMATINIB      ABL1     True  0.119476   \n",
       "2     IMATINIB     BIRC5     True  0.016854   \n",
       "3     IMATINIB      ULK3     True  0.733151   \n",
       "4     IMATINIB       NF1     True  0.031876   \n",
       "..         ...       ...      ...       ...   \n",
       "299  CISPLATIN  MPHOSPH8     True  0.003043   \n",
       "300  CISPLATIN      MDM2     True  0.013811   \n",
       "301  CISPLATIN     MLLT3     True  0.179547   \n",
       "302  CISPLATIN      MAPT     True  0.000814   \n",
       "303  CISPLATIN      IFNG     True  0.025650   \n",
       "\n",
       "                                interaction_attributes  \\\n",
       "0                        Fusion Protein: FIP1L1:PDGFRA   \n",
       "1    Mechanism of Action: Inhibition| Endogenous Dr...   \n",
       "2                                                        \n",
       "3                                                        \n",
       "4               Alteration: NF1:.| Alteration: NF1:del   \n",
       "..                                                 ...   \n",
       "299                                                      \n",
       "300                               Alteration: MDM2:amp   \n",
       "301                                                      \n",
       "302                                                      \n",
       "303                                                      \n",
       "\n",
       "                                                source      pmid  \n",
       "0    FDA Pharmacogenomic Biomarkers | PharmGKB - Th...  24433361  \n",
       "1    The ChEMBL Bioactivity Database | Drug Target ...            \n",
       "2                                NCI Cancer Gene Index  16254145  \n",
       "3        PharmGKB - The Pharmacogenomics Knowledgebase  15073101  \n",
       "4                            Cancer Genome Interpreter            \n",
       "..                                                 ...       ...  \n",
       "299                                Drug Target Commons            \n",
       "300                          Cancer Genome Interpreter            \n",
       "301      PharmGKB - The Pharmacogenomics Knowledgebase            \n",
       "302                                Drug Target Commons            \n",
       "303                              NCI Cancer Gene Index   8044830  \n",
       "\n",
       "[304 rows x 7 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugs = ['imatinib','encorafenib','cisplatin','aspirin','fake']\n",
    "dgi_data = dgipy.get_interactions(drugs, search='drugs')\n",
    "dgi_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>application</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA078340</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 100MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA079179</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 400MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA204285</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 400MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 100MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA206547</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 400MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA207495</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 100MG BASE Discontinued ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA207586</td>\n",
       "      <td>none</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA208302</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 400MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA208429</td>\n",
       "      <td>none</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA210658</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 100MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA212135</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 400MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>ANDA212773</td>\n",
       "      <td>IMATINIB MESYLATE: EQ 400MG BASE Prescription ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>IMATINIB</td>\n",
       "      <td>NDA021588</td>\n",
       "      <td>GLEEVEC: EQ 100MG BASE Prescription TABLET | G...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>ENCORAFENIB</td>\n",
       "      <td>NDA210496</td>\n",
       "      <td>BRAFTOVI: 50MG Discontinued CAPSULE | BRAFTOVI...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>ASPIRIN</td>\n",
       "      <td>NDA203697</td>\n",
       "      <td>VAZALORE: 81MG Over-the-counter CAPSULE | VAZA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA074656</td>\n",
       "      <td>CISPLATIN: 1MG/ML Prescription INJECTABLE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA074735</td>\n",
       "      <td>CISPLATIN: 1MG/ML Prescription INJECTABLE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA075036</td>\n",
       "      <td>CISPLATIN: 1MG/ML Prescription INJECTABLE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA206774</td>\n",
       "      <td>CISPLATIN: 1MG/ML Prescription INJECTABLE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>CISPLATIN: 1MG/ML Prescription INJECTABLE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>NDA018057</td>\n",
       "      <td>PLATINOL-AQ: 0.5MG/ML Discontinued INJECTABLE ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "           drug application                                        description\n",
       "0      IMATINIB  ANDA078340  IMATINIB MESYLATE: EQ 100MG BASE Prescription ...\n",
       "1      IMATINIB  ANDA079179  IMATINIB MESYLATE: EQ 400MG BASE Prescription ...\n",
       "2      IMATINIB  ANDA204285  IMATINIB MESYLATE: EQ 400MG BASE Prescription ...\n",
       "3      IMATINIB  ANDA204644  IMATINIB MESYLATE: EQ 100MG BASE Prescription ...\n",
       "4      IMATINIB  ANDA206547  IMATINIB MESYLATE: EQ 400MG BASE Prescription ...\n",
       "5      IMATINIB  ANDA207495  IMATINIB MESYLATE: EQ 100MG BASE Discontinued ...\n",
       "6      IMATINIB  ANDA207586                                               none\n",
       "7      IMATINIB  ANDA208302  IMATINIB MESYLATE: EQ 400MG BASE Prescription ...\n",
       "8      IMATINIB  ANDA208429                                               none\n",
       "9      IMATINIB  ANDA210658  IMATINIB MESYLATE: EQ 100MG BASE Prescription ...\n",
       "10     IMATINIB  ANDA212135  IMATINIB MESYLATE: EQ 400MG BASE Prescription ...\n",
       "11     IMATINIB  ANDA212773  IMATINIB MESYLATE: EQ 400MG BASE Prescription ...\n",
       "12     IMATINIB   NDA021588  GLEEVEC: EQ 100MG BASE Prescription TABLET | G...\n",
       "13  ENCORAFENIB   NDA210496  BRAFTOVI: 50MG Discontinued CAPSULE | BRAFTOVI...\n",
       "14      ASPIRIN   NDA203697  VAZALORE: 81MG Over-the-counter CAPSULE | VAZA...\n",
       "15    CISPLATIN  ANDA074656          CISPLATIN: 1MG/ML Prescription INJECTABLE\n",
       "16    CISPLATIN  ANDA074735          CISPLATIN: 1MG/ML Prescription INJECTABLE\n",
       "17    CISPLATIN  ANDA075036          CISPLATIN: 1MG/ML Prescription INJECTABLE\n",
       "18    CISPLATIN  ANDA206774          CISPLATIN: 1MG/ML Prescription INJECTABLE\n",
       "19    CISPLATIN  ANDA207323          CISPLATIN: 1MG/ML Prescription INJECTABLE\n",
       "20    CISPLATIN   NDA018057  PLATINOL-AQ: 0.5MG/ML Discontinued INJECTABLE ..."
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_apps = dgipy.get_drug_applications(drugs)\n",
    "drug_apps"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load FDA Data, Filter Search Space\n",
    "Load previously downloaded FDA data set (JSON format). Define search space using the previously obtained ANDA/NDA applications via DGIpy. Filter the FDA data set using this search space definition. NOTE: I think it will be important to maintain the *brand_name* and *application_number* sections throughout any downstream data manipulation to maintain the ability to somehow link it back to paired DGI data.  \n",
    "  \n",
    "I also think this method would be used to obtain search chunks for any question answering or generative tasks that may be desirable (ala RAG technique that James presented)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brand_name</th>\n",
       "      <th>application_number</th>\n",
       "      <th>adverse_reactions</th>\n",
       "      <th>indications_and_usage</th>\n",
       "      <th>contraindications</th>\n",
       "      <th>warnings_and_cautions</th>\n",
       "      <th>warnings</th>\n",
       "      <th>precautions</th>\n",
       "      <th>pharmacokinetics</th>\n",
       "      <th>purpose</th>\n",
       "      <th>clinical_pharmacology</th>\n",
       "      <th>active_ingredient</th>\n",
       "      <th>stop_use</th>\n",
       "      <th>boxed_warning</th>\n",
       "      <th>pharmacodynamics</th>\n",
       "      <th>pharmacogenomics</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Imatinib</td>\n",
       "      <td>ANDA206547</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None . None ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin should be administered unde...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207495</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207586</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          brand_name application_number  \\\n",
       "0           Imatinib         ANDA206547   \n",
       "1          Cisplatin         ANDA207323   \n",
       "2  Imatinib Mesylate         ANDA207495   \n",
       "3  Imatinib Mesylate         ANDA204644   \n",
       "4  Imatinib Mesylate         ANDA207586   \n",
       "\n",
       "                                   adverse_reactions  \\\n",
       "0  6 ADVERSE REACTIONS The following serious adve...   \n",
       "1  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "2  6 ADVERSE REACTIONS The following serious adve...   \n",
       "3  6 ADVERSE REACTIONS The following serious adve...   \n",
       "4  6 ADVERSE REACTIONS The following serious adve...   \n",
       "\n",
       "                               indications_and_usage  \\\n",
       "0  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "1  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "2  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "3  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "4  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "\n",
       "                                   contraindications  \\\n",
       "0              4 CONTRAINDICATIONS None . None ( 4 )   \n",
       "1  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "2                4 CONTRAINDICATIONS None. None. (4)   \n",
       "3              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "4              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "\n",
       "                               warnings_and_cautions  \\\n",
       "0  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "1                                                NaN   \n",
       "2  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "3  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "4  5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "\n",
       "                                            warnings  \\\n",
       "0                                                NaN   \n",
       "1  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                                         precautions  \\\n",
       "0                                                NaN   \n",
       "1  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                                    pharmacokinetics purpose  \\\n",
       "0  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "1                                                NaN     NaN   \n",
       "2  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "3  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "4                                                NaN     NaN   \n",
       "\n",
       "                               clinical_pharmacology active_ingredient  \\\n",
       "0  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "1  CLINICAL PHARMACOLOGY Plasma concentrations of...               NaN   \n",
       "2  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "3  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "4  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "\n",
       "  stop_use                                      boxed_warning  \\\n",
       "0      NaN                                                NaN   \n",
       "1      NaN  WARNINGS Cisplatin should be administered unde...   \n",
       "2      NaN                                                NaN   \n",
       "3      NaN                                                NaN   \n",
       "4      NaN                                                NaN   \n",
       "\n",
       "  pharmacodynamics pharmacogenomics  \n",
       "0              NaN              NaN  \n",
       "1              NaN              NaN  \n",
       "2              NaN              NaN  \n",
       "3              NaN              NaN  \n",
       "4              NaN              NaN  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# from datasets import Dataset\n",
    "import pandas as pd\n",
    "drugs_at_fda = pd.read_excel('../data/openfda-2.xlsx').reset_index(drop=True).drop('Unnamed: 0', axis=1)\n",
    "\n",
    "relevant_labels = list(set(drug_apps['application']))\n",
    "search_set = drugs_at_fda[drugs_at_fda['application_number'].isin(relevant_labels)].reset_index(drop=True)\n",
    "search_set[0:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## LLM Methods\n",
    "Previous workflow test used a rudimentary implementation of the huggingface ecosystem. For this instance, test some of the gpt4all local models to see if this is a feasible application. The model we will use first is the general purpose *mistral-7b-instruct-v0*"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "import llm\n",
    "model = llm.get_model('mistral-7b-instruct-v0')\n",
    "conversation = model.conversation()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Indications\n",
    "Separate into chunks, can you answer questions about the chunks? Also can you extract information about them?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1416\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'1 INDICATIONS AND USAGE BRAFTOVI is a kinase inhibitor indicated: • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC. ( 1.3 , 5.2 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma BRAFTOVI ® is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy [see Dosage and Administration (2.1) ] . 1.3 Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC [see Warnings and Precautions (5.2) ] .'"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Clinical Pharmacology section for BRAFTOVI\n",
    "test = drugs_at_fda[drugs_at_fda['brand_name']==\"BRAFTOVI\"].reset_index(drop=True)['indications_and_usage'][0]\n",
    "print(len(test))\n",
    "test\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " The text describes the indications and limitations of use for Braftovi, a kinase inhibitor used to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy. However, it is not indicated for treatment of patients with wild-type BRAF melanoma or CRC.\n"
     ]
    }
   ],
   "source": [
    "response = conversation.prompt(f'Summarize Text Chunk #1: {test}')\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Response prompt='from the previous text chunk, identify the subject therapeutic, its indications for use, and any additional interactions.' text=' The subject therapeutic in this text chunk is Braftovi, a kinase inhibitor. Its indications for use are:\n",
       "- In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n",
       "- In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy.\n",
       "It is important to note that Braftovi is not indicated for treatment of patients with wild-type BRAF melanoma or CRC. Additionally, there are no additional interactions mentioned in this text chunk.'>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response2 = conversation.prompt('from the previous text chunk, identify the subject therapeutic, its indications for use, and any additional interactions.')\n",
    "response2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\n",
      "\"Subject Therapeutic\": \"Braftovi\",\n",
      "\"Indications for Use\": [\n",
      "{\n",
      "\"Melanoma with BRAF V600E or V600K mutation\": true\n",
      "},\n",
      "{\n",
      "\"Metastatic colorectal cancer (CRC) with BRAF V600E mutation after prior therapy\": true\n",
      "}\n",
      "],\n",
      "\"Additional Interactions\": []\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "response3 = conversation.prompt('Format your previous answer as JSON. Be sure to label the subject therapeutic, indications, and any additional interactions.')\n",
    "print(response3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\n",
      "\"Subject Therapeutic\": \"Braftovi\",\n",
      "\"Indications for Use\": [\n",
      "{\n",
      "\"Melanoma with BRAF V600E or V600K mutation\": true\n",
      "},\n",
      "{\n",
      "\"Metastatic colorectal cancer (CRC) with BRAF V600E mutation after prior therapy\": true\n",
      "}\n",
      "],\n",
      "\"Additional Interactions\": []\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "response4 = conversation.prompt('from text chunk #1, identify the subject therapeutic, its indications for use, and any additional interactions. Format your response in JSON.')\n",
    "print(response4)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Indications, Again"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1416\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'1 INDICATIONS AND USAGE BRAFTOVI is a kinase inhibitor indicated: • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC. ( 1.3 , 5.2 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma BRAFTOVI ® is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy [see Dosage and Administration (2.1) ] . 1.3 Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC [see Warnings and Precautions (5.2) ] .'"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Clinical Pharmacology section for BRAFTOVI\n",
    "test = drugs_at_fda[drugs_at_fda['brand_name']==\"BRAFTOVI\"].reset_index(drop=True)['indications_and_usage'][0]\n",
    "print(len(test))\n",
    "test\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# New conversation\n",
    "conversation = model.conversation()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " The text chunk provides information about the indications and limitations of use for Braftovi, a kinase inhibitor used to treat patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy. However, it is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC.\n"
     ]
    }
   ],
   "source": [
    "response = conversation.prompt(f'Summarize Text Chunk #1: {test}')\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this is an intended JSON format: {\"subject_therapeutic\": <value>, \"indications_for_use\": <value>, \"additional_interactions\": <value>}\n"
     ]
    }
   ],
   "source": [
    "print(f'this is my intended JSON format: {{\"subject_therapeutic\": <value>, \"indications_for_use\": <value>, \"additional_interactions\": <value>}}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Response prompt='This is my intended JSON format: {\"subject_therapeutic\": <value>, \"indications_for_use\": <value>, \"additional_interactions\": <value>}. From the previous text chunk, identify the subject therapeutic, its indications for use, and any additional interactions. Format your answer using my intended JSON format.' text=' {\"subject_therapeutic\": \"Braftovi\", \"indications_for_use\": [\"unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test\", \"metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy\"], \"additional_interactions\": []}'>"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response2 = conversation.prompt(f'This is my intended JSON format: {{\"subject_therapeutic\": <value>, \"indications_for_use\": <value>, \"additional_interactions\": <value>}}. From the previous text chunk, identify the subject therapeutic, its indications for use, and any additional interactions. Format your answer using my intended JSON format.')\n",
    "response2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' {\"subject_therapeutic\": \"Braftovi\", \"indications_for_use\": [\"unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test\", \"metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy\"], \"additional_interactions\": []}'"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response2.text()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Batch Indications\n",
    "Single test for indications seems potentially good, let's try batching all our therapeutics and find out where the roadblocks happen. I suspect figuring out the context window and how to properly chunk longer sections will be the biggest issue."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Attempt 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brand_name</th>\n",
       "      <th>application_number</th>\n",
       "      <th>adverse_reactions</th>\n",
       "      <th>indications_and_usage</th>\n",
       "      <th>contraindications</th>\n",
       "      <th>warnings_and_cautions</th>\n",
       "      <th>warnings</th>\n",
       "      <th>precautions</th>\n",
       "      <th>pharmacokinetics</th>\n",
       "      <th>purpose</th>\n",
       "      <th>clinical_pharmacology</th>\n",
       "      <th>active_ingredient</th>\n",
       "      <th>stop_use</th>\n",
       "      <th>boxed_warning</th>\n",
       "      <th>pharmacodynamics</th>\n",
       "      <th>pharmacogenomics</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Imatinib</td>\n",
       "      <td>ANDA206547</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None . None ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin should be administered unde...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207495</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207586</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          brand_name application_number  \\\n",
       "0           Imatinib         ANDA206547   \n",
       "1          Cisplatin         ANDA207323   \n",
       "2  Imatinib Mesylate         ANDA207495   \n",
       "3  Imatinib Mesylate         ANDA204644   \n",
       "4  Imatinib Mesylate         ANDA207586   \n",
       "\n",
       "                                   adverse_reactions  \\\n",
       "0  6 ADVERSE REACTIONS The following serious adve...   \n",
       "1  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "2  6 ADVERSE REACTIONS The following serious adve...   \n",
       "3  6 ADVERSE REACTIONS The following serious adve...   \n",
       "4  6 ADVERSE REACTIONS The following serious adve...   \n",
       "\n",
       "                               indications_and_usage  \\\n",
       "0  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "1  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "2  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "3  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "4  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "\n",
       "                                   contraindications  \\\n",
       "0              4 CONTRAINDICATIONS None . None ( 4 )   \n",
       "1  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "2                4 CONTRAINDICATIONS None. None. (4)   \n",
       "3              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "4              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "\n",
       "                               warnings_and_cautions  \\\n",
       "0  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "1                                                NaN   \n",
       "2  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "3  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "4  5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "\n",
       "                                            warnings  \\\n",
       "0                                                NaN   \n",
       "1  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                                         precautions  \\\n",
       "0                                                NaN   \n",
       "1  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                                    pharmacokinetics purpose  \\\n",
       "0  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "1                                                NaN     NaN   \n",
       "2  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "3  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "4                                                NaN     NaN   \n",
       "\n",
       "                               clinical_pharmacology active_ingredient  \\\n",
       "0  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "1  CLINICAL PHARMACOLOGY Plasma concentrations of...               NaN   \n",
       "2  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "3  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "4  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "\n",
       "  stop_use                                      boxed_warning  \\\n",
       "0      NaN                                                NaN   \n",
       "1      NaN  WARNINGS Cisplatin should be administered unde...   \n",
       "2      NaN                                                NaN   \n",
       "3      NaN                                                NaN   \n",
       "4      NaN                                                NaN   \n",
       "\n",
       "  pharmacodynamics pharmacogenomics  \n",
       "0              NaN              NaN  \n",
       "1              NaN              NaN  \n",
       "2              NaN              NaN  \n",
       "3              NaN              NaN  \n",
       "4              NaN              NaN  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication_search = search_set[search_set['indications_and_usage'].isnull()==False].reset_index(drop=True)\n",
    "indication_search[0:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import llm\n",
    "model = llm.get_model('mistral-7b-instruct-v0')\n",
    "\n",
    "def ask_mistral(text): # Something weird about being inside a function????????\n",
    "    conversation = model.conversation()\n",
    "    response = conversation.prompt(f'Summarize Text Chunk #1: {text}')\n",
    "    response2 = conversation.prompt(f'This is my intended JSON format: {{\"subject_therapeutic\": <value>, \"indications_for_use\": <value>, \"additional_interactions\": <value>}}. From Text Chunk #1, identify the subject therapeutic, its indications for use, and any additional interactions. Format your answer using my intended JSON format.')\n",
    "\n",
    "    return(response2.text())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "indication_search['json'] = indication_search['indications_and_usage'].apply(ask_mistral)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brand_name</th>\n",
       "      <th>indications_and_usage</th>\n",
       "      <th>json</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Imatinib</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Vitamin D\", \"indicat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Acetaminophen\", \"ind...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>CISplatin</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>VAZALORE</td>\n",
       "      <td>Uses Uses For temporary relief of minor aches ...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>BRAFTOVI</td>\n",
       "      <td>1 INDICATIONS AND USAGE BRAFTOVI is a kinase i...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>INDICATIONS AND USAGE: Cisplatin Injection is ...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin for injectio...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Acetaminophen\", \"ind...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>VAZALORE</td>\n",
       "      <td>Uses For temporary relief of minor aches and p...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Vitamin D\", \"indicat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>INDICATIONS AND USAGE Cisplatin Injection is i...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Statins\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin Injection is...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Gleevec</td>\n",
       "      <td>1 INDICATIONS AND USAGE Gleevec is a kinase in...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>CISplatin</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Statins\",\\n  \"in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Imatinib mesylate 400 mg</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Acetaminophen\",\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin injection is...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Antidepressants\", \"i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin injection is...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>{\"subject_therapeutic\": \"Vitamin D\", \"indicat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Imatinib mesylate</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>{\\n  \"subject_therapeutic\": \"Antidepressants\"...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                  brand_name  \\\n",
       "0                   Imatinib   \n",
       "1                  Cisplatin   \n",
       "2          Imatinib Mesylate   \n",
       "3          Imatinib Mesylate   \n",
       "4          Imatinib Mesylate   \n",
       "5                  CISplatin   \n",
       "6                   VAZALORE   \n",
       "7          Imatinib Mesylate   \n",
       "8                   BRAFTOVI   \n",
       "9          imatinib mesylate   \n",
       "10                 Cisplatin   \n",
       "11                 Cisplatin   \n",
       "12         Imatinib Mesylate   \n",
       "13                  VAZALORE   \n",
       "14                 Cisplatin   \n",
       "15         imatinib mesylate   \n",
       "16         imatinib mesylate   \n",
       "17         Imatinib Mesylate   \n",
       "18                 Cisplatin   \n",
       "19         imatinib mesylate   \n",
       "20         Imatinib Mesylate   \n",
       "21                   Gleevec   \n",
       "22         Imatinib mesylate   \n",
       "23                 CISPLATIN   \n",
       "24                 CISplatin   \n",
       "25  Imatinib mesylate 400 mg   \n",
       "26         Imatinib Mesylate   \n",
       "27         Imatinib Mesylate   \n",
       "28         Imatinib Mesylate   \n",
       "29         imatinib mesylate   \n",
       "30         Imatinib Mesylate   \n",
       "31         Imatinib Mesylate   \n",
       "32         Imatinib mesylate   \n",
       "33         Imatinib Mesylate   \n",
       "34                 Cisplatin   \n",
       "35                 Cisplatin   \n",
       "36                 CISPLATIN   \n",
       "37         Imatinib mesylate   \n",
       "\n",
       "                                indications_and_usage  \\\n",
       "0   1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "1   INDICATIONS Cisplatin Injection is indicated a...   \n",
       "2   1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "3   1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "4   1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "5   INDICATIONS Cisplatin Injection is indicated a...   \n",
       "6   Uses Uses For temporary relief of minor aches ...   \n",
       "7   1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "8   1 INDICATIONS AND USAGE BRAFTOVI is a kinase i...   \n",
       "9   1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "10  INDICATIONS AND USAGE: Cisplatin Injection is ...   \n",
       "11  1 INDICATIONS AND USAGE Cisplatin for injectio...   \n",
       "12  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "13  Uses For temporary relief of minor aches and p...   \n",
       "14  INDICATIONS AND USAGE Cisplatin Injection is i...   \n",
       "15  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "16  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "17  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "18  1 INDICATIONS AND USAGE Cisplatin Injection is...   \n",
       "19  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "20  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "21  1 INDICATIONS AND USAGE Gleevec is a kinase in...   \n",
       "22  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "23  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "24  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "25  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "26  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "27  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "28  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "29  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "30  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "31  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "32  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "33  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "34  1 INDICATIONS AND USAGE Cisplatin injection is...   \n",
       "35  1 INDICATIONS AND USAGE Cisplatin injection is...   \n",
       "36  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "37  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "\n",
       "                                                 json  \n",
       "0    {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "1    {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "2    {\"subject_therapeutic\": \"Vitamin D\", \"indicat...  \n",
       "3    {\"subject_therapeutic\": \"Acetaminophen\", \"ind...  \n",
       "4    {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "5    {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "6    {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "7    {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "8    {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "9    {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "10   {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "11   {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "12   {\"subject_therapeutic\": \"Acetaminophen\", \"ind...  \n",
       "13   {\"subject_therapeutic\": \"Vitamin D\", \"indicat...  \n",
       "14   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "15   {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "16   {\"subject_therapeutic\": \"Statins\", \"indicatio...  \n",
       "17   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "18   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "19   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "20   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "21   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "22   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "23   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "24   {\\n  \"subject_therapeutic\": \"Statins\",\\n  \"in...  \n",
       "25   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "26   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "27   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "28   {\\n  \"subject_therapeutic\": \"Acetaminophen\",\\...  \n",
       "29   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "30   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "31   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "32   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "33   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "34   {\"subject_therapeutic\": \"Antidepressants\", \"i...  \n",
       "35   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  \n",
       "36   {\"subject_therapeutic\": \"Vitamin D\", \"indicat...  \n",
       "37   {\\n  \"subject_therapeutic\": \"Antidepressants\"...  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication_search[['brand_name','indications_and_usage','json']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'subject_therapeutic': 'Antidepressants',\n",
       " 'indications_for_use': 'Treatment of depression, anxiety disorders, and other psychiatric conditions',\n",
       " 'additional_interactions': 'May interact with certain medications such as blood thinners, sedatives, and stimulants'}"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import ast\n",
    "ast.literal_eval(indication_search['json'][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.'"
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication_search['indications_and_usage'][0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Attempt #2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brand_name</th>\n",
       "      <th>application_number</th>\n",
       "      <th>adverse_reactions</th>\n",
       "      <th>indications_and_usage</th>\n",
       "      <th>contraindications</th>\n",
       "      <th>warnings_and_cautions</th>\n",
       "      <th>warnings</th>\n",
       "      <th>precautions</th>\n",
       "      <th>pharmacokinetics</th>\n",
       "      <th>purpose</th>\n",
       "      <th>clinical_pharmacology</th>\n",
       "      <th>active_ingredient</th>\n",
       "      <th>stop_use</th>\n",
       "      <th>boxed_warning</th>\n",
       "      <th>pharmacodynamics</th>\n",
       "      <th>pharmacogenomics</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Imatinib</td>\n",
       "      <td>ANDA206547</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None . None ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin should be administered unde...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207495</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207586</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          brand_name application_number  \\\n",
       "0           Imatinib         ANDA206547   \n",
       "1          Cisplatin         ANDA207323   \n",
       "2  Imatinib Mesylate         ANDA207495   \n",
       "3  Imatinib Mesylate         ANDA204644   \n",
       "4  Imatinib Mesylate         ANDA207586   \n",
       "\n",
       "                                   adverse_reactions  \\\n",
       "0  6 ADVERSE REACTIONS The following serious adve...   \n",
       "1  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "2  6 ADVERSE REACTIONS The following serious adve...   \n",
       "3  6 ADVERSE REACTIONS The following serious adve...   \n",
       "4  6 ADVERSE REACTIONS The following serious adve...   \n",
       "\n",
       "                               indications_and_usage  \\\n",
       "0  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "1  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "2  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "3  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "4  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "\n",
       "                                   contraindications  \\\n",
       "0              4 CONTRAINDICATIONS None . None ( 4 )   \n",
       "1  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "2                4 CONTRAINDICATIONS None. None. (4)   \n",
       "3              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "4              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "\n",
       "                               warnings_and_cautions  \\\n",
       "0  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "1                                                NaN   \n",
       "2  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "3  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "4  5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "\n",
       "                                            warnings  \\\n",
       "0                                                NaN   \n",
       "1  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                                         precautions  \\\n",
       "0                                                NaN   \n",
       "1  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                                    pharmacokinetics purpose  \\\n",
       "0  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "1                                                NaN     NaN   \n",
       "2  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "3  12.3 Pharmacokinetics The pharmacokinetics of ...     NaN   \n",
       "4                                                NaN     NaN   \n",
       "\n",
       "                               clinical_pharmacology active_ingredient  \\\n",
       "0  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "1  CLINICAL PHARMACOLOGY Plasma concentrations of...               NaN   \n",
       "2  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "3  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "4  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...               NaN   \n",
       "\n",
       "  stop_use                                      boxed_warning  \\\n",
       "0      NaN                                                NaN   \n",
       "1      NaN  WARNINGS Cisplatin should be administered unde...   \n",
       "2      NaN                                                NaN   \n",
       "3      NaN                                                NaN   \n",
       "4      NaN                                                NaN   \n",
       "\n",
       "  pharmacodynamics pharmacogenomics  \n",
       "0              NaN              NaN  \n",
       "1              NaN              NaN  \n",
       "2              NaN              NaN  \n",
       "3              NaN              NaN  \n",
       "4              NaN              NaN  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication_search = search_set[search_set['indications_and_usage'].isnull()==False].reset_index(drop=True)\n",
    "indication_search[0:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase (1.1)\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2)\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) (1.3)\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4)\",\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# # Test block\n",
    "# model = 'reset'\n",
    "# model = llm.get_model('mistral-7b-instruct-v0')\n",
    "# text = indication_search[\"indications_and_usage\"][0]\n",
    "# response2 = model.prompt(f'Read the following text and identify the subject therapeutic, its indications for use, and any additional interactions. Keep your indications brief and format your answer using this JSON format: {{\"subject_therapeutic\": <value>, \"indications_for_use\": [<value>], \"additional_interactions\": [<value>]}}. \\n Text: {text} ')\n",
    "\n",
    "# # response = conversation.prompt(f'Remember this text as Chunk 1: {text}')\n",
    "# # response2 = conversation.prompt(f'Read the following text and identify the subject therapeutic, its indications for use, and any additional interactions. Keep your indications brief and format your answer using this JSON format: {{\"subject_therapeutic\": <value>, \"indications_for_use\": [<value>], \"additional_interactions\": [<value>]}}. \\n Text: {text} ')\n",
    "# print(response2.text())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  3%|▎         | 1/38 [04:51<2:59:45, 291.51s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase (1.1)\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2)\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) (1.3)\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4)\",\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  5%|▌         | 2/38 [06:13<1:40:53, 168.15s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  8%|▊         | 3/38 [10:50<2:07:12, 218.08s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myel\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 11%|█         | 4/38 [15:28<2:16:54, 241.61s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myel\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 13%|█▎        | 5/38 [20:08<2:20:32, 255.53s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myeloprol\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 16%|█▌        | 6/38 [21:30<1:44:49, 196.56s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 18%|█▊        | 7/38 [22:08<1:14:41, 144.58s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"aspirin\", \"indications_for_use\": [\"temporary relief of minor aches and pains associated with headache\", \"backache\", \"muscular aches\", \"cold toothache\", \"minor pains of arthritis\", \"premenstrual and menstrual cramps\"]}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 21%|██        | 8/38 [26:46<1:33:33, 187.11s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy\", \"Adult patients with myelodysplastic/myeloproliferative diseases (MDS/\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 24%|██▎       | 9/38 [28:41<1:19:30, 164.51s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Braftovi\", \"indications_for_use\": [\"Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\", \"Adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.\"]}.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 26%|██▋       | 10/38 [33:22<1:33:35, 200.54s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myel\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 29%|██▉       | 11/38 [34:44<1:13:55, 164.27s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 32%|███▏      | 12/38 [35:29<55:26, 127.94s/it]  "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin\", \"indications_for_use\": [\"Advanced testicular cancer\", \"Advanced ovarian cancer\", \"Advanced bladder cancer\"]}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 34%|███▍      | 13/38 [40:06<1:12:06, 173.06s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1)\", \n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2)\", \n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3)\", \n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 37%|███▋      | 14/38 [40:42<52:38, 131.61s/it]  "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"aspirin\", \"indications_for_use\": [\"temporary relief of minor aches and pains associated with headache Backache muscular aches a cold toothache minor pains of arthritis premenstrual and menstrual cramps temporarily redices fever\"]}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 39%|███▉      | 15/38 [42:04<44:43, 116.67s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radio therapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 42%|████▏     | 16/38 [46:40<1:00:23, 164.73s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myeloprol\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 45%|████▍     | 17/38 [51:17<1:09:25, 198.38s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myeloprol\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 47%|████▋     | 18/38 [55:22<1:10:51, 212.56s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy\", \"Adult patients with myelodysplastic/myeloproliferative diseases (MDS/\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 50%|█████     | 19/38 [56:11<51:45, 163.46s/it]  "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Advanced testicular cancer\", \"Advanced ovarian cancer\", \"Advanced bladder cancer\"]}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 53%|█████▎    | 20/38 [1:00:50<59:24, 198.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene re\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 55%|█████▌    | 21/38 [1:05:45<1:04:21, 227.14s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene re\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 58%|█████▊    | 22/38 [1:14:04<1:22:21, 308.85s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Gleevec\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myeloproliferative diseases\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 61%|██████    | 23/38 [1:18:17<1:12:57, 291.85s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements as determined with an FDA-approved test\", \"Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 63%|██████▎   | 24/38 [1:19:48<54:02, 231.60s/it]  "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radio therapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 66%|██████▌   | 25/38 [1:21:18<41:01, 189.34s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 68%|██████▊   | 26/38 [1:25:32<41:45, 208.77s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements as determined with an FDA-approved test\", \"Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 71%|███████   | 27/38 [1:29:45<40:41, 221.97s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test\", \"Adult patients with\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 74%|███████▎  | 28/38 [1:35:11<42:10, 253.05s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myeloprol\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 76%|███████▋  | 29/38 [1:40:39<41:20, 275.66s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy\", \"Adult patients with myelodysplastic/myeloproliferative diseases (MDS/\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 79%|███████▉  | 30/38 [1:48:39<44:55, 336.99s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myel\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 82%|████████▏ | 31/38 [1:53:04<36:47, 315.37s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements as determined with an FDA-approved test\", \"Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 84%|████████▍ | 32/38 [1:58:47<32:20, 323.49s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate tablets\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myel\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 87%|████████▋ | 33/38 [2:03:55<26:35, 319.06s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements as determined with an FDA-approved test\", \"Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 89%|████████▉ | 34/38 [2:09:45<21:53, 328.33s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\",\n",
      "\"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.\",\n",
      "\"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).\",\n",
      "\"Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.\",\n",
      "\"Adult patients with myelodysplastic/myeloprol\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 92%|█████████▏| 35/38 [2:10:39<12:17, 245.94s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin injection\", \"indications_for_use\": [\"Advanced testicular cancer\", \"Advanced ovarian cancer\", \"Advanced bladder cancer\"]}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 95%|█████████▍| 36/38 [2:11:39<06:20, 190.21s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin injection\", \"indications_for_use\": [\"Advanced testicular cancer\", \"Advanced ovarian cancer\", \"Advanced bladder cancer\"]}\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 97%|█████████▋| 37/38 [2:13:21<02:43, 163.68s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Cisplatin Injection\", \"indications_for_use\": [\"Metastatic Testicular Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radio therapeutic procedures.\", \n",
      "\"Metastatic Ovarian Tumors\", \"Established combination therapy with other approved chemotherapeutic agents in patients who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide.\", \n",
      "\"Advanced Bladder Cancer\", \"Single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.\"]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 38/38 [2:18:02<00:00, 217.95s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " {\"subject_therapeutic\": \"Imatinib mesylate\", \"indications_for_use\": [\"Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase\", \"Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy\", \"Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)\", \"Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements as determined with an FDA-approved test\", \"Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "import llm\n",
    "model = llm.get_model('mistral-7b-instruct-v0')\n",
    "from tqdm import tqdm\n",
    "\n",
    "\n",
    "index_pos = 0\n",
    "indication_search['json'] = 'empty'\n",
    "\n",
    "for indication in tqdm(indication_search['indications_and_usage']):\n",
    "    model = 'reset'\n",
    "    model = llm.get_model('mistral-7b-instruct-v0')\n",
    "\n",
    "    response = model.prompt(f'Read the following text and identify the subject therapeutic, its indications for use, and any additional interactions. Format your answer using this JSON format: {{\"subject_therapeutic\": <value>, \"indications_for_use\": [<value>]}}. \\n Text: {indication}. Be sure to close your JSON tags. ')\n",
    "\n",
    "    print(response.text())\n",
    "    indication_search['json'][index_pos] = response.text()\n",
    "    index_pos += 1\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brand_name</th>\n",
       "      <th>application_number</th>\n",
       "      <th>adverse_reactions</th>\n",
       "      <th>indications_and_usage</th>\n",
       "      <th>contraindications</th>\n",
       "      <th>warnings_and_cautions</th>\n",
       "      <th>warnings</th>\n",
       "      <th>precautions</th>\n",
       "      <th>pharmacokinetics</th>\n",
       "      <th>purpose</th>\n",
       "      <th>clinical_pharmacology</th>\n",
       "      <th>active_ingredient</th>\n",
       "      <th>stop_use</th>\n",
       "      <th>boxed_warning</th>\n",
       "      <th>pharmacodynamics</th>\n",
       "      <th>pharmacogenomics</th>\n",
       "      <th>json</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Imatinib</td>\n",
       "      <td>ANDA206547</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None . None ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin should be administered unde...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207495</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA207586</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>CISplatin</td>\n",
       "      <td>ANDA075036</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING Cisplatin Injection should be administ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>VAZALORE</td>\n",
       "      <td>NDA203697</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uses Uses For temporary relief of minor aches ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Warnings Reye’s Syndrome: Children an...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active Ingredient (in Each capsules) Purposes:...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ACTIVE iNGREDIENT Active Ingredient (in Each c...</td>\n",
       "      <td>Do not use I f you have ever had an allergic r...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"aspirin\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA079179</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None ( 4 ).</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>BRAFTOVI</td>\n",
       "      <td>NDA210496</td>\n",
       "      <td>6 ADVERSE REACTIONS The following adverse reac...</td>\n",
       "      <td>1 INDICATIONS AND USAGE BRAFTOVI is a kinase i...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • New Primary Malig...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.2 Pharmacodynamics Cardiac Electrophysiolog...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"BRAFTOVI\", \"indicati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>ANDA212135</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA074735</td>\n",
       "      <td>ADVERSE REACTIONS: Nephrotoxicity Dose-related...</td>\n",
       "      <td>INDICATIONS AND USAGE: Cisplatin Injection is ...</td>\n",
       "      <td>CONTRAINDICATIONS: Cisplatin is contraindicate...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS: Cisplatin produces cumulative nephro...</td>\n",
       "      <td>PRECAUTIONS: Peripheral blood counts should be...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY: Plasma concentrations o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING Cisplatin should be administered under...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>NDA018057</td>\n",
       "      <td>6 ADVERSE REACTIONS The following adverse reac...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin for injectio...</td>\n",
       "      <td>4 CONTRAINDICATIONS Cisplatin for injection is...</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Hypersensitivity ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics Distribution Cisplatin d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin\", \"indicat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204285</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>VAZALORE</td>\n",
       "      <td>NDA203697</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uses For temporary relief of minor aches and p...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Warnings Warnings Reye’s Syndrome: Children an...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Purposes: Aspirin (NSAID)* 325mg __ Pain relie...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Active Ingredient (in Each capsules) Aspirin (...</td>\n",
       "      <td>Stop use and ask a doctor Stop use and ask a d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"aspirin\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS AND USAGE Cisplatin Injection is i...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING Cisplatin should be administered under...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>ANDA078340</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS · Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>ANDA078340</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS · Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA078340</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA074656</td>\n",
       "      <td>6 ADVERSE REACTIONS The following adverse reac...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin Injection is...</td>\n",
       "      <td>4 CONTRAINDICATIONS Cisplatin Injection is con...</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Hypersensitivity re...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics Distribution Cisplatin d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>ANDA210658</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Gleevec</td>\n",
       "      <td>NDA021588</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Gleevec is a kinase in...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Gleevec\", \"indicatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Imatinib mesylate</td>\n",
       "      <td>ANDA208302</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>4 CONTRAINDICATIONS None None.</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BOXED WARNING Cisplatin should be administered...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>CISplatin</td>\n",
       "      <td>NDA018057</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING Cisplatin Injection should be administ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Imatinib mesylate 400 mg</td>\n",
       "      <td>ANDA208302</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>4 CONTRAINDICATIONS None None (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA208429</td>\n",
       "      <td>6 ADVERSE REACTIONS The most frequently report...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None ( 4 ) None</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA212773</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA079179</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None ( 4 ).</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>imatinib mesylate</td>\n",
       "      <td>ANDA212135</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA208302</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None None (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA204644</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate tabl...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. ( 4 )</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS • Edema and severe ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Imatinib mesylate</td>\n",
       "      <td>ANDA208302</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>4 CONTRAINDICATIONS None None (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Imatinib Mesylate</td>\n",
       "      <td>ANDA212773</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Imatinib mesylate is a...</td>\n",
       "      <td>4 CONTRAINDICATIONS None. None. (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA206774</td>\n",
       "      <td>6 ADVERSE REACTIONS The following adverse reac...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin injection is...</td>\n",
       "      <td>4 CONTRAINDICATIONS Cisplatin injection is con...</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Hypersensitivity re...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics Distribution Cisplatin d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Cisplatin</td>\n",
       "      <td>ANDA206774</td>\n",
       "      <td>6 ADVERSE REACTIONS The following adverse reac...</td>\n",
       "      <td>1 INDICATIONS AND USAGE Cisplatin injection is...</td>\n",
       "      <td>4 CONTRAINDICATIONS Cisplatin injection is con...</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Hypersensitivity re...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics Distribution Cisplatin d...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>CISPLATIN</td>\n",
       "      <td>ANDA207323</td>\n",
       "      <td>ADVERSE REACTIONS Nephrotoxicity Dose-related ...</td>\n",
       "      <td>INDICATIONS Cisplatin Injection is indicated a...</td>\n",
       "      <td>CONTRAINDICATIONS Cisplatin is contraindicated...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WARNINGS Cisplatin produces cumulative nephrot...</td>\n",
       "      <td>PRECAUTIONS Peripheral blood counts should be ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CLINICAL PHARMACOLOGY Plasma concentrations of...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BOXED WARNING Cisplatin should be administered...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Cisplatin Injection\"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Imatinib mesylate</td>\n",
       "      <td>ANDA208302</td>\n",
       "      <td>6 ADVERSE REACTIONS The following serious adve...</td>\n",
       "      <td>1 INDICATIONS &amp; USAGE Imatinib mesylate is a k...</td>\n",
       "      <td>4 CONTRAINDICATIONS None None (4)</td>\n",
       "      <td>5 WARNINGS AND PRECAUTIONS Edema and severe fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12.3 Pharmacokinetics The pharmacokinetics of ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>{\"subject_therapeutic\": \"Imatinib mesylate\", ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                  brand_name application_number  \\\n",
       "0                   Imatinib         ANDA206547   \n",
       "1                  Cisplatin         ANDA207323   \n",
       "2          Imatinib Mesylate         ANDA207495   \n",
       "3          Imatinib Mesylate         ANDA204644   \n",
       "4          Imatinib Mesylate         ANDA207586   \n",
       "5                  CISplatin         ANDA075036   \n",
       "6                   VAZALORE          NDA203697   \n",
       "7          Imatinib Mesylate         ANDA079179   \n",
       "8                   BRAFTOVI          NDA210496   \n",
       "9          imatinib mesylate         ANDA212135   \n",
       "10                 Cisplatin         ANDA074735   \n",
       "11                 Cisplatin          NDA018057   \n",
       "12         Imatinib Mesylate         ANDA204285   \n",
       "13                  VAZALORE          NDA203697   \n",
       "14                 Cisplatin         ANDA207323   \n",
       "15         imatinib mesylate         ANDA078340   \n",
       "16         imatinib mesylate         ANDA078340   \n",
       "17         Imatinib Mesylate         ANDA078340   \n",
       "18                 Cisplatin         ANDA074656   \n",
       "19         imatinib mesylate         ANDA210658   \n",
       "20         Imatinib Mesylate         ANDA204644   \n",
       "21                   Gleevec          NDA021588   \n",
       "22         Imatinib mesylate         ANDA208302   \n",
       "23                 CISPLATIN         ANDA207323   \n",
       "24                 CISplatin          NDA018057   \n",
       "25  Imatinib mesylate 400 mg         ANDA208302   \n",
       "26         Imatinib Mesylate         ANDA208429   \n",
       "27         Imatinib Mesylate         ANDA212773   \n",
       "28         Imatinib Mesylate         ANDA079179   \n",
       "29         imatinib mesylate         ANDA212135   \n",
       "30         Imatinib Mesylate         ANDA208302   \n",
       "31         Imatinib Mesylate         ANDA204644   \n",
       "32         Imatinib mesylate         ANDA208302   \n",
       "33         Imatinib Mesylate         ANDA212773   \n",
       "34                 Cisplatin         ANDA206774   \n",
       "35                 Cisplatin         ANDA206774   \n",
       "36                 CISPLATIN         ANDA207323   \n",
       "37         Imatinib mesylate         ANDA208302   \n",
       "\n",
       "                                    adverse_reactions  \\\n",
       "0   6 ADVERSE REACTIONS The following serious adve...   \n",
       "1   ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "2   6 ADVERSE REACTIONS The following serious adve...   \n",
       "3   6 ADVERSE REACTIONS The following serious adve...   \n",
       "4   6 ADVERSE REACTIONS The following serious adve...   \n",
       "5   ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "6                                                 NaN   \n",
       "7   6 ADVERSE REACTIONS The following serious adve...   \n",
       "8   6 ADVERSE REACTIONS The following adverse reac...   \n",
       "9   6 ADVERSE REACTIONS The following serious adve...   \n",
       "10  ADVERSE REACTIONS: Nephrotoxicity Dose-related...   \n",
       "11  6 ADVERSE REACTIONS The following adverse reac...   \n",
       "12  6 ADVERSE REACTIONS The following serious adve...   \n",
       "13                                                NaN   \n",
       "14  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "15  6 ADVERSE REACTIONS The following serious adve...   \n",
       "16  6 ADVERSE REACTIONS The following serious adve...   \n",
       "17  6 ADVERSE REACTIONS The following serious adve...   \n",
       "18  6 ADVERSE REACTIONS The following adverse reac...   \n",
       "19  6 ADVERSE REACTIONS The following serious adve...   \n",
       "20  6 ADVERSE REACTIONS The following serious adve...   \n",
       "21  6 ADVERSE REACTIONS The following serious adve...   \n",
       "22  6 ADVERSE REACTIONS The following serious adve...   \n",
       "23  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "24  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "25  6 ADVERSE REACTIONS The following serious adve...   \n",
       "26  6 ADVERSE REACTIONS The most frequently report...   \n",
       "27  6 ADVERSE REACTIONS The following serious adve...   \n",
       "28  6 ADVERSE REACTIONS The following serious adve...   \n",
       "29  6 ADVERSE REACTIONS The following serious adve...   \n",
       "30  6 ADVERSE REACTIONS The following serious adve...   \n",
       "31  6 ADVERSE REACTIONS The following serious adve...   \n",
       "32  6 ADVERSE REACTIONS The following serious adve...   \n",
       "33  6 ADVERSE REACTIONS The following serious adve...   \n",
       "34  6 ADVERSE REACTIONS The following adverse reac...   \n",
       "35  6 ADVERSE REACTIONS The following adverse reac...   \n",
       "36  ADVERSE REACTIONS Nephrotoxicity Dose-related ...   \n",
       "37  6 ADVERSE REACTIONS The following serious adve...   \n",
       "\n",
       "                                indications_and_usage  \\\n",
       "0   1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "1   INDICATIONS Cisplatin Injection is indicated a...   \n",
       "2   1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "3   1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "4   1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "5   INDICATIONS Cisplatin Injection is indicated a...   \n",
       "6   Uses Uses For temporary relief of minor aches ...   \n",
       "7   1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "8   1 INDICATIONS AND USAGE BRAFTOVI is a kinase i...   \n",
       "9   1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "10  INDICATIONS AND USAGE: Cisplatin Injection is ...   \n",
       "11  1 INDICATIONS AND USAGE Cisplatin for injectio...   \n",
       "12  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "13  Uses For temporary relief of minor aches and p...   \n",
       "14  INDICATIONS AND USAGE Cisplatin Injection is i...   \n",
       "15  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "16  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "17  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "18  1 INDICATIONS AND USAGE Cisplatin Injection is...   \n",
       "19  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "20  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "21  1 INDICATIONS AND USAGE Gleevec is a kinase in...   \n",
       "22  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "23  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "24  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "25  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "26  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "27  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "28  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "29  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "30  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "31  1 INDICATIONS AND USAGE Imatinib mesylate tabl...   \n",
       "32  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "33  1 INDICATIONS AND USAGE Imatinib mesylate is a...   \n",
       "34  1 INDICATIONS AND USAGE Cisplatin injection is...   \n",
       "35  1 INDICATIONS AND USAGE Cisplatin injection is...   \n",
       "36  INDICATIONS Cisplatin Injection is indicated a...   \n",
       "37  1 INDICATIONS & USAGE Imatinib mesylate is a k...   \n",
       "\n",
       "                                    contraindications  \\\n",
       "0               4 CONTRAINDICATIONS None . None ( 4 )   \n",
       "1   CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "2                 4 CONTRAINDICATIONS None. None. (4)   \n",
       "3               4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "4               4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "5   CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "6                                                 NaN   \n",
       "7               4 CONTRAINDICATIONS None. None ( 4 ).   \n",
       "8               4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "9               4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "10  CONTRAINDICATIONS: Cisplatin is contraindicate...   \n",
       "11  4 CONTRAINDICATIONS Cisplatin for injection is...   \n",
       "12              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "13                                                NaN   \n",
       "14  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "15              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "16              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "17              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "18  4 CONTRAINDICATIONS Cisplatin Injection is con...   \n",
       "19               4 CONTRAINDICATIONS None. None ( 4 )   \n",
       "20              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "21              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "22                     4 CONTRAINDICATIONS None None.   \n",
       "23  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "24  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "25                  4 CONTRAINDICATIONS None None (4)   \n",
       "26                4 CONTRAINDICATIONS None ( 4 ) None   \n",
       "27                4 CONTRAINDICATIONS None. None. (4)   \n",
       "28              4 CONTRAINDICATIONS None. None ( 4 ).   \n",
       "29              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "30                  4 CONTRAINDICATIONS None None (4)   \n",
       "31              4 CONTRAINDICATIONS None. None. ( 4 )   \n",
       "32                  4 CONTRAINDICATIONS None None (4)   \n",
       "33                4 CONTRAINDICATIONS None. None. (4)   \n",
       "34  4 CONTRAINDICATIONS Cisplatin injection is con...   \n",
       "35  4 CONTRAINDICATIONS Cisplatin injection is con...   \n",
       "36  CONTRAINDICATIONS Cisplatin is contraindicated...   \n",
       "37                  4 CONTRAINDICATIONS None None (4)   \n",
       "\n",
       "                                warnings_and_cautions  \\\n",
       "0   5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "1                                                 NaN   \n",
       "2   5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "3   5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "4   5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7   5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "8   5 WARNINGS AND PRECAUTIONS • New Primary Malig...   \n",
       "9   5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "10                                                NaN   \n",
       "11  5 WARNINGS AND PRECAUTIONS • Hypersensitivity ...   \n",
       "12  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15  5 WARNINGS AND PRECAUTIONS · Edema and severe ...   \n",
       "16  5 WARNINGS AND PRECAUTIONS · Edema and severe ...   \n",
       "17  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "18  5 WARNINGS AND PRECAUTIONS Hypersensitivity re...   \n",
       "19  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "20  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "21  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "22  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "26  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "27  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "28  5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "29  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "30  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "31  5 WARNINGS AND PRECAUTIONS • Edema and severe ...   \n",
       "32  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "33  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "34  5 WARNINGS AND PRECAUTIONS Hypersensitivity re...   \n",
       "35  5 WARNINGS AND PRECAUTIONS Hypersensitivity re...   \n",
       "36                                                NaN   \n",
       "37  5 WARNINGS AND PRECAUTIONS Edema and severe fl...   \n",
       "\n",
       "                                             warnings  \\\n",
       "0                                                 NaN   \n",
       "1   WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5   WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "6   WARNINGS Warnings Reye’s Syndrome: Children an...   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10  WARNINGS: Cisplatin produces cumulative nephro...   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13  Warnings Warnings Reye’s Syndrome: Children an...   \n",
       "14  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "24  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "36  WARNINGS Cisplatin produces cumulative nephrot...   \n",
       "37                                                NaN   \n",
       "\n",
       "                                          precautions  \\\n",
       "0                                                 NaN   \n",
       "1   PRECAUTIONS Peripheral blood counts should be ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5   PRECAUTIONS Peripheral blood counts should be ...   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10  PRECAUTIONS: Peripheral blood counts should be...   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "24  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "36  PRECAUTIONS Peripheral blood counts should be ...   \n",
       "37                                                NaN   \n",
       "\n",
       "                                     pharmacokinetics  \\\n",
       "0   12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "1                                                 NaN   \n",
       "2   12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "3   12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6                                                 NaN   \n",
       "7   12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "8   12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "9   12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "10                                                NaN   \n",
       "11  12.3 Pharmacokinetics Distribution Cisplatin d...   \n",
       "12  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "13                                                NaN   \n",
       "14                                                NaN   \n",
       "15  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "16  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "17  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "18  12.3 Pharmacokinetics Distribution Cisplatin d...   \n",
       "19  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "20  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "21  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "22  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "26  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "27  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "28  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "29  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "30  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "31  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "32  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "33  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "34  12.3 Pharmacokinetics Distribution Cisplatin d...   \n",
       "35  12.3 Pharmacokinetics Distribution Cisplatin d...   \n",
       "36                                                NaN   \n",
       "37  12.3 Pharmacokinetics The pharmacokinetics of ...   \n",
       "\n",
       "                                              purpose  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6   Active Ingredient (in Each capsules) Purposes:...   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13  Purposes: Aspirin (NSAID)* 325mg __ Pain relie...   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "\n",
       "                                clinical_pharmacology  \\\n",
       "0   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "1   CLINICAL PHARMACOLOGY Plasma concentrations of...   \n",
       "2   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "3   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "4   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "5   CLINICAL PHARMACOLOGY Plasma concentrations of...   \n",
       "6                                                 NaN   \n",
       "7   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "8   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "9   12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "10  CLINICAL PHARMACOLOGY: Plasma concentrations o...   \n",
       "11  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "12  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "13                                                NaN   \n",
       "14  CLINICAL PHARMACOLOGY Plasma concentrations of...   \n",
       "15  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "16  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "17  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "18  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "19  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "20  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "21  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "22  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "23  CLINICAL PHARMACOLOGY Plasma concentrations of...   \n",
       "24  CLINICAL PHARMACOLOGY Plasma concentrations of...   \n",
       "25  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "26  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "27  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "28  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "29  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "30  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "31  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "32  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "33  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "34  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "35  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "36  CLINICAL PHARMACOLOGY Plasma concentrations of...   \n",
       "37  12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Act...   \n",
       "\n",
       "                                    active_ingredient  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6   ACTIVE iNGREDIENT Active Ingredient (in Each c...   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13  Active Ingredient (in Each capsules) Aspirin (...   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "\n",
       "                                             stop_use  \\\n",
       "0                                                 NaN   \n",
       "1                                                 NaN   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5                                                 NaN   \n",
       "6   Do not use I f you have ever had an allergic r...   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10                                                NaN   \n",
       "11                                                NaN   \n",
       "12                                                NaN   \n",
       "13  Stop use and ask a doctor Stop use and ask a d...   \n",
       "14                                                NaN   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18                                                NaN   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23                                                NaN   \n",
       "24                                                NaN   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34                                                NaN   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "\n",
       "                                        boxed_warning  \\\n",
       "0                                                 NaN   \n",
       "1   WARNINGS Cisplatin should be administered unde...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4                                                 NaN   \n",
       "5   WARNING Cisplatin Injection should be administ...   \n",
       "6                                                 NaN   \n",
       "7                                                 NaN   \n",
       "8                                                 NaN   \n",
       "9                                                 NaN   \n",
       "10  WARNING Cisplatin should be administered under...   \n",
       "11  WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...   \n",
       "12                                                NaN   \n",
       "13                                                NaN   \n",
       "14  WARNING Cisplatin should be administered under...   \n",
       "15                                                NaN   \n",
       "16                                                NaN   \n",
       "17                                                NaN   \n",
       "18  WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22                                                NaN   \n",
       "23  BOXED WARNING Cisplatin should be administered...   \n",
       "24  WARNING Cisplatin Injection should be administ...   \n",
       "25                                                NaN   \n",
       "26                                                NaN   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                                                NaN   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33                                                NaN   \n",
       "34  WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...   \n",
       "35  WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY...   \n",
       "36  BOXED WARNING Cisplatin should be administered...   \n",
       "37                                                NaN   \n",
       "\n",
       "                                     pharmacodynamics pharmacogenomics  \\\n",
       "0                                                 NaN              NaN   \n",
       "1                                                 NaN              NaN   \n",
       "2                                                 NaN              NaN   \n",
       "3                                                 NaN              NaN   \n",
       "4                                                 NaN              NaN   \n",
       "5                                                 NaN              NaN   \n",
       "6                                                 NaN              NaN   \n",
       "7                                                 NaN              NaN   \n",
       "8   12.2 Pharmacodynamics Cardiac Electrophysiolog...              NaN   \n",
       "9                                                 NaN              NaN   \n",
       "10                                                NaN              NaN   \n",
       "11                                                NaN              NaN   \n",
       "12                                                NaN              NaN   \n",
       "13                                                NaN              NaN   \n",
       "14                                                NaN              NaN   \n",
       "15                                                NaN              NaN   \n",
       "16                                                NaN              NaN   \n",
       "17                                                NaN              NaN   \n",
       "18                                                NaN              NaN   \n",
       "19                                                NaN              NaN   \n",
       "20                                                NaN              NaN   \n",
       "21                                                NaN              NaN   \n",
       "22                                                NaN              NaN   \n",
       "23                                                NaN              NaN   \n",
       "24                                                NaN              NaN   \n",
       "25                                                NaN              NaN   \n",
       "26                                                NaN              NaN   \n",
       "27                                                NaN              NaN   \n",
       "28                                                NaN              NaN   \n",
       "29                                                NaN              NaN   \n",
       "30                                                NaN              NaN   \n",
       "31                                                NaN              NaN   \n",
       "32                                                NaN              NaN   \n",
       "33                                                NaN              NaN   \n",
       "34                                                NaN              NaN   \n",
       "35                                                NaN              NaN   \n",
       "36                                                NaN              NaN   \n",
       "37                                                NaN              NaN   \n",
       "\n",
       "                                                 json  \n",
       "0    {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "1    {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "2    {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "3    {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "4    {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "5    {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "6    {\"subject_therapeutic\": \"aspirin\", \"indicatio...  \n",
       "7    {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "8    {\"subject_therapeutic\": \"BRAFTOVI\", \"indicati...  \n",
       "9    {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "10   {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "11   {\"subject_therapeutic\": \"Cisplatin\", \"indicat...  \n",
       "12   {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "13   {\"subject_therapeutic\": \"aspirin\", \"indicatio...  \n",
       "14   {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "15   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "16   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "17   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "18   {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "19   {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "20   {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "21   {\"subject_therapeutic\": \"Gleevec\", \"indicatio...  \n",
       "22   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "23   {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "24   {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "25   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "26   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "27   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "28   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "29   {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "30   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "31   {\"subject_therapeutic\": \"Imatinib mesylate ta...  \n",
       "32   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "33   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  \n",
       "34   {\"subject_therapeutic\": \"Cisplatin injection\"...  \n",
       "35   {\"subject_therapeutic\": \"Cisplatin injection\"...  \n",
       "36   {\"subject_therapeutic\": \"Cisplatin Injection\"...  \n",
       "37   {\"subject_therapeutic\": \"Imatinib mesylate\", ...  "
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "indication_search"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Scratch"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "projectname",
   "language": "python",
   "name": "projectname"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
